StreetInsider.com News Articles

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) has entered into definitive agreements for the immediate exercise of certain outstanding warrants, expected to generate approximately $5.9 million in gross proceeds before placement agent fees and other expenses.

The transaction involves the exercise of warrants to purchase an aggregate of 453,969 shares of common stock at a reduced exercise price of $12.92 per share. The warrants were originally issued on four separate dates between February 2024 and December 2025, with original exercise prices ranging from $17.85 to $45.90 per share. The transaction is expected to close on or about September 9, 2026, subject to

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) released its annual letter from CEO Richard Christopher detailing the company's 2025 achievements and outlining plans for 2026. The biotechnology company focuses on drug delivery platforms using its proprietary DehydraTECH technology.

During 2025, Lexaria conducted multiple human and animal studies examining its technology with three major GLP-1 drugs: semaglutide, tirzepatide, and liraglutide. The company completed its first Phase 1b registrational study in Australia and received 10 additional patents, expanding its portfolio to 56 patents worldwide.

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0400

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0400

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0400

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders.

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0400

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0400

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0400

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria reports additional Phase 1b study results for drug delivery platform

Tue, 30 Dec 2025 09:20:15 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) released additional results from its Phase 1b clinical study examining its DehydraTECH drug delivery platform compared to Rybelsus in 126 overweight, obese, pre-diabetic and type-2 diabetic participants over 12 weeks.

The study found no statistically significant differences between DehydraTECH arms and Rybelsus control in secondary efficacy parameters including mean fasting glucose, cholesterol, and LDL cholesterol at week 16.

Body composition analysis showed the DehydraTECH-semaglutide arm had a lean mass reduction of 0.41 kg compared to 1.72 kg for Rybelsus, representing 37.96% of total weight loss versus 48.45% for the control arm. The DehydraTECH-CBD arm demonstrated blood pressure

Lexaria reports additional Phase 1b study results for drug delivery platform

Tue, 30 Dec 2025 09:20:15 -0400

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0400

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm.

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0400

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0400

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0400

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria achieves primary endpoint in Phase 1b GLP-1 study

Tue, 23 Dec 2025 09:29:16 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that its Phase 1b study GLP-1-H24-4 successfully achieved its primary endpoint, demonstrating that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus®.

The 12-week study conducted in Australia involved 126 overweight, obese, pre-diabetic and type-2 diabetic participants across five treatment arms. The primary endpoint assessed safety and tolerability based on treatment emergent adverse events.

DehydraTECH-semaglutide showed a 47.9% reduction in total adverse events compared to Rybelsus® and a statistically significant 54.9% reduction in gastrointestinal adverse events. All four DehydraTECH treatment arms demonstrated lower rates of overall and gastrointestinal adverse

Lexaria achieves primary endpoint in Phase 1b GLP-1 study

Tue, 23 Dec 2025 09:29:16 -0400

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Tue, 23 Dec 2025 09:29:00 -0400

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus^®
DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus^®
Recent financings create runway for prospective new 2026 development opportunities

KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4